News

MSDC-0602, an insulin sensitizer is selective for a molecular target, mTOT, which connects mitochondrial metabolism to important cell functions. Recent Phase 2a study in patients suffering with type

Heplisav when given as 2 doses over 4 weeks in modified intent to treat (MITT) analysis of adults with type II diabetes protected a greater proportion of subjects

The VSS technology is a computer vision technology consisting of Rfid sensors and software programs that utilize complex algorithms to process and analyze the imagery. The system detects

The SafeGuard is designed to provide life extendity to the analytical column without any compromises in the chromatographic performance. TraceGold GC Columns with SafeGuard are used in a

NCINIs inhibits HIV integrase by binding to a novel site and target the key component of the HIV virus. BI 224436 has been evaluated in a Phase 1a

The companies, under the licensing and Cooperative Research and Development Agreements (CRADA) will also develop a technology platform based on NCI’s cancer vaccine technology. In addition, Bavarian Nordic

Neratinib is a multi-targeted, irreversible tyrosine kinase inhibitor (TKI) oral drug which targets the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases. Neratinib is being studied in the

The new partnership includes recruitment and development of contract sales force specializing in medical food sales for lead therapeutic, Vascazen, a therapeutic by Pivotal. Pivotal Therapeutics president Rachelle

The research company will receive $11.7m for toxicology studies and an additional $2.6 m for pharmacology and pharmacokinetics studies which will be conducted through NCI’s Developmental Therapeutics Program.